{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-029343","form_type":"8-K","ticker":"INSM","cik":"0001104506","company_name":"INSMED Inc","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.350948+00:00","generated_at":"2026-05-17T17:05:17.457653+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Insmed Q2 net loss $321.7M ($1.70/sh); ARIKAYCE revenue $107.4M (+19% YoY)","bullets":["ARIKAYCE global revenue $107.4M, up 19% vs Q2 2024; US revenue $68.7M (+7.7%).","Net loss $321.7M vs $300.6M a year ago; R&D spend $177.2M, SG&A $154.8M on brensocatib launch prep.","Cash & securities $1.9B; full-year ARIKAYCE revenue guidance reaffirmed at $405-425M.","Brensocatib PDUFA date Aug 12, 2025; Phase 3 TPIP in PH-ILD to start H2 2025.","Completed $823.1M equity offering in June; redeemed $569.5M convertible notes in April/May."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-029343","json":"https://secwatch.observer/filing/0001140361-25-029343.json","markdown":"https://secwatch.observer/filing/0001140361-25-029343.md","text":"https://secwatch.observer/filing/0001140361-25-029343.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/0001140361-25-029343-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:05:17.457653+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}